User login

Biologics protection, Canada's patent utility regime among PhRMA's NAFTA priorities

June 16, 2017 at 5:46 PM
The Pharmaceutical Research and Manufacturers of America wants a renegotiated NAFTA to tackle a slew of complaints it has with how Canada and Mexico handle pharmaceutical intellectual property and enforce existing NAFTA obligations, arguing that the failure to do so will hinder U.S. export and manufacturing of drugs. PhRMA, in comments on NAFTA renegotiation objectives submitted to the Office of the U.S. Trade Representative this week, said the redo should serve as a vehicle to address patentability standards in Canada,...

Not a subscriber? Sign up for 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.